{ "schema_version": "chamgap-public-evidence-check-1.0", "public_id": "v3055-s0", "verdict_number": "3055", "title": "Raw or heat-treated ginger powder, 2 g/day × Reduction of muscle pain 24 hours after eccentric exercise", "view_version": "1.0", "view_created_date": "2026-10-25", "criteria_version": "1.0", "criteria_date": "2026-10-06", "review_date": "2026-10-06", "legacy_evidence_date": "2026-09-08", "review_scope": { "materials_read": "Retained Korean/English summaries and case-specific condition/application records", "clinical_papers_directly_read": false, "new_clinical_search": false, "limitation": "Prepared from retained summaries and condition-application records. External abstracts, full texts, registration, protocols and analysis plans remain unread. Historical review records do not establish current independent clinical validation.", "date_meaning": "2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time." }, "claim_context": { "population": "Healthy adult volunteers; the original samples are 34 and 40, with formulation mapping, per-arm randomized/analyzed/completed counts and selection/training details unverified", "dose": "Nominally 2 g/day; dosing frequency, exercise day and interval from the last dose to assessment remain unverified", "comparator": "Matching placebo; composition, sensory matching, actual use and co-intervention details remain unverified", "endpoint": "Pain intensity 24 hours after eccentric elbow-flexor exercise; the scale, absolute unit and preregistered hierarchy remain unverified", "intervention": "Oral raw ginger-rhizome powder capsules from Zingiber officinale; raw-material processing, batch composition and actual content remain unverified", "duration": "11 days of dosing; only 24-hour pain is selected within 3 days of postexercise follow-up", "excluded_extensions": [ "Adding the heat-treated formulation as independent replication, placebo for raw powder, or a comparison establishing formulation superiority or equivalence", "Combining 48- or 72-hour pain, strength, ROM, CK or inflammatory markers into the same result", "Treating a single-dose crossover trial as the same regimen as repeated dosing", "Extending to guaranteed exercise recovery, prevention of muscle injury, or other patient or training populations", "Establishing an optimal dose, persistence after stopping, long-term effects or specific subgroup effects", "Substituting foods, extracts, essential oils, topical or combination products, or other doses", "Establishing overall safety, causal harms, incidence, personal dosing or replacement of exercise-injury treatment" ] }, "requirements": [ { "item_id": "N01", "question_type": "Evidence condition", "question": "Which raw ginger-powder capsule comparison was selected as this sheet's single question?", "needed": "The current retained record and final boundary selection, with locations of formulation-specific results; later confirmation of formulation and comparator in the original protocol.", "role": "Required", "role_reason": "The parent question describes raw and heat-treated formulations together, so attribution of the raw ginger-powder capsule result needs to be traced as a separate question.", "application_exception": "This formulation-specific comparison is a derived question identifier, not an index in the original subclaim list. The other formulation is not deleted, and no new clinical score is assigned.", "criterion": "Link the selected formulation, oral 2 g/day, 11 days, healthy adults, placebo and 24-hour pain, while distinguishing the parent question, other formulation and original arrays.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: The current retained record and final boundary selection, with locations of formulation-specific results; later confirmation of formulation and comparator in the original protocol. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The selected comparison is raw ginger-powder capsules, 2 g/day for 11 days, versus matching placebo for pain intensity 24 hours after eccentric elbow-flexor exercise. The original claim is ‘reduction of muscle pain 24 hours after eccentric exercise’; the original subclaim list is empty, and the parent is the original verdict.", "condition_status": "Met", "status_reason": "Met means that the retained record, selected boundary and limited identity of the derived question are linked. It does not establish sufficient efficacy evidence or full-text verification.", "missingness": "The complete paper and registration defining the regimen remain unread in this work; no new grade is assigned to either formulation.", "uncertainty": "The complete paper and registration defining the regimen remain unread in this work; no new grade is assigned to either formulation.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "The current retained record and final boundary selection, with locations of formulation-specific results; later confirmation of formulation and comparator in the original protocol." }, { "item_id": "N02", "question_type": "Evidence condition", "question": "Is the raw ginger-powder capsule result being counted as replication by two independent research teams?", "needed": "Protocols, registration, participant overlap and recruitment periods for the two experiments, plus a map linking related reports.", "role": "Required", "role_reason": "Reports, experiments and team independence need to be distinguished so that the two sheets are not read as a count of independent replications.", "application_exception": "S01 contains two experiments, but this sheet selects one formulation versus placebo. The samples of 34/40 are not summed into unique participants, and overlap with S02 is not inferred.", "criterion": "Link the original statement that S01 contains two experiments in one paper by the same team to the different S02 regimen, leaving unconfirmed total unique participants unverified.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Protocols, registration, participant overlap and recruitment periods for the two experiments, plus a map linking related reports. This records needed materials; no new research was executed.", "current_reports": [ "S01", "S02" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The S01 design is recorded as 2 randomized, double-blind, placebo-controlled experiments by the same team. The central explanation explicitly describes two experiments in the same paper, team and protocol. S02 is a separate single-dose crossover report.", "condition_status": "Met", "status_reason": "Met applies to preserving the verified report/family relationship. It does not mean the total number of unique trials or participant overlap has been resolved.", "missingness": "Actual registration identifiers, denominator stages and participant overlap between the two experiments, and overlap with S02, remain unverified.", "uncertainty": "Actual registration identifiers, denominator stages and participant overlap between the two experiments, and overlap with S02, remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Protocols, registration, participant overlap and recruitment periods for the two experiments, plus a map linking related reports." }, { "item_id": "N03", "question_type": "Evidence condition", "question": "What material was actually read when preparing the raw ginger-powder capsule sheet?", "needed": "The current retained summary, original source locations and identity, actual review date and separate material-specific access records.", "role": "Required", "role_reason": "It is necessary to distinguish actual reading of the local summary from reading the original abstract or full text.", "application_exception": "Reading the retained English summary is not reading the full English paper. Summary-reading links point to the retained source location and identity.", "criterion": "Read all Korean/English text, intervention/population details, axes, evidence, bibliography and corrections in the retained original summary, linking the locations and source identity.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: The current retained summary, original source locations and identity, actual review date and separate material-specific access records. This records needed materials; no new research was executed.", "current_reports": [ "S01", "S02" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "All Korean/English text, intervention/population details, assessment axes, 2 evidence summaries, 2 bibliography entries, 1 correction and the original empty arrays in the current retained summary were read. The material read was the local summary; external clinical literature was not read in this work.", "condition_status": "Met", "status_reason": "Met applies to the recorded acquisition and reading of the local summary and its exact source locations.", "missingness": "No current reading of the original abstract, full text, registration or protocol/SAP.", "uncertainty": "No current reading of the original abstract, full text, registration or protocol/SAP.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "The current retained summary, original source locations and identity, actual review date and separate material-specific access records." }, { "item_id": "N04", "question_type": "Evidence condition", "question": "Do the raw ginger-powder capsule PubMed and DOI links also establish current reading of those materials?", "needed": "Actual acquired original/abstract, registration and protocol/SAP files, with success/failure, version and reading-date records.", "role": "Required", "role_reason": "Providing a safe link must not be mistaken for reading an abstract/full text or confirming that registration exists.", "application_exception": "External links are not visited in this work. An unidentified registration does not establish that the trial was unregistered or that registration is absent.", "criterion": "Distinguish entry points constructed from original bibliography URLs and DOIs from unacquired full text, registration and plans for each material. Do not label unattempted access as failed access.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Actual acquired original/abstract, registration and protocol/SAP files, with success/failure, version and reading-date records. This records needed materials; no new research was executed.", "current_reports": [ "S01", "S02" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The two original PubMed URLs and DOIs are retained. Current external access was not attempted, and material was neither acquired nor read. Exact full-text files, registration URLs and protocol/SAP material also remain unverified.", "condition_status": "Unverified", "status_reason": "Current external access, identity and content have not been verified for each material. Local-summary reading remains separately identified.", "missingness": "Current external responses, abstracts/full texts, registration and planning content remain unverified; there is no basis to classify access as unavailable.", "uncertainty": "Current external responses, abstracts/full texts, registration and planning content remain unverified; there is no basis to classify access as unavailable.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Actual acquired original/abstract, registration and protocol/SAP files, with success/failure, version and reading-date records." }, { "item_id": "N05", "question_type": "Evidence condition", "question": "How were the healthy adults contributing to the raw ginger-powder capsule result selected?", "needed": "Eligibility, recruitment setting, baseline characteristics, training status and formulation-specific population tables for each experiment.", "role": "Required", "role_reason": "The label healthy adults does not establish applicability to all ages, training levels or patients with injuries.", "application_exception": "The original samples of 34 and 40 describe populations; they are not assigned as the analysis denominator for this formulation.", "criterion": "Distinguish the verified description of healthy adult volunteers from unverified age, sex, exercise training, recruitment and exclusion details.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Eligibility, recruitment setting, baseline characteristics, training status and formulation-specific population tables for each experiment. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The retained population is healthy adult volunteers in samples of 34 and 40. Specific age, sex, training status and recruitment conditions are not linked to raw ginger-powder capsules by formulation in the local summary.", "condition_status": "Partly verified", "status_reason": "Healthy adult volunteers are identified, while selection and representativeness details remain unverified.", "missingness": "Formulation-specific age, sex, training, recruitment, inclusion/exclusion and baseline balance remain unverified.", "uncertainty": "Formulation-specific age, sex, training, recruitment, inclusion/exclusion and baseline balance remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Eligibility, recruitment setting, baseline characteristics, training status and formulation-specific population tables for each experiment." }, { "item_id": "N06", "question_type": "Evidence condition", "question": "How much of the actual formulation and ingredient specification of raw ginger-powder capsules is verified?", "needed": "Product/batch and raw-material specifications, drying/grinding and processing of raw powder, gingerol/shogaol batch content and actual content per capsule for the selected experiment.", "role": "Required", "role_reason": "Even with the same 2 g label, raw ginger-powder capsules cannot be substituted by heat-treated ginger-powder capsules, food, extracts or essential oils.", "application_exception": "Nominal powder mass is not converted into an active-ingredient dose, and another formulation's result does not replace batch verification.", "criterion": "Identify raw ginger-powder capsules as a distinct formulation, retaining uncertainty about drying/grinding, raw-material processing, gingerol/shogaol batch content, purity and actual capsule content.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Product/batch and raw-material specifications, drying/grinding and processing of raw powder, gingerol/shogaol batch content and actual content per capsule for the selected experiment. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original intervention description groups raw-powder and heat-treated-powder capsules together, while the original result distinguishes raw ginger-powder capsules: 25%, −0.78 SD, P=.041. Drying/grinding, raw-material processing and gingerol/shogaol batch content of the raw powder remain unverified in the retained summary.", "condition_status": "Partly verified", "status_reason": "The selected formulation and attribution of the original result are identified, while complete product, processing and active-specification matching remains unverified.", "missingness": "Drying/grinding, raw-material processing, gingerol/shogaol batch content, actual content, batch and capsule specifications of the raw powder remain unverified.", "uncertainty": "Drying/grinding, raw-material processing, gingerol/shogaol batch content, actual content, batch and capsule specifications of the raw powder remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Product/batch and raw-material specifications, drying/grinding and processing of raw powder, gingerol/shogaol batch content and actual content per capsule for the selected experiment." }, { "item_id": "N07", "question_type": "Evidence condition", "question": "What are the 2 g/day, 11-day dosing and exercise/assessment schedules for raw ginger-powder capsules?", "needed": "Formulation-specific dosing logs, capsule frequency, first/last dose, exercise workload and assessment-time protocol.", "role": "Required", "role_reason": "It is necessary to avoid confusing single dosing with 11-day repeated dosing or replacing treatment duration with follow-up duration.", "application_exception": "Do not fill in a particular exercise day within the 11 days from outside the retained record. Timing of the single 2 g comparison remains separate context.", "criterion": "Link nominal oral 2 g/day for 11 days to the selected 24-hour assessment within 3 days of postexercise follow-up, without inferring the exact dosing/exercise schedule.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Formulation-specific dosing logs, capsule frequency, first/last dose, exercise workload and assessment-time protocol. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The selected raw ginger-powder capsule regimen is oral 2 g/day for 11 days. The retained duration also describes 3 days of postexercise follow-up, with pain at 24 hours designated as the principal endpoint. The exact exercise day, dosing frequency and interval from the last dose remain unverified.", "condition_status": "Partly verified", "status_reason": "Nominal dose, route, duration and selected follow-up time are known, while actual logs and schedule details remain unverified.", "missingness": "Exercise workload, dosing start/end, daily frequency and the last-dose/assessment interval remain unverified.", "uncertainty": "Exercise workload, dosing start/end, daily frequency and the last-dose/assessment interval remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Formulation-specific dosing logs, capsule frequency, first/last dose, exercise workload and assessment-time protocol." }, { "item_id": "N08", "question_type": "Evidence condition", "question": "Which placebo was compared with raw ginger-powder capsules, and in which direction?", "needed": "Composition, mass, capsule/taste/odor matching and actual allocated use of placebo in the relevant experiment.", "role": "Required", "role_reason": "It is necessary to avoid turning the result into a direct raw-versus-heat-treated comparison or an uncontrolled within-group change.", "application_exception": "The heat-treated ginger-powder capsule result is not used as placebo for raw ginger-powder capsules. A matching label alone does not establish successful sensory blinding.", "criterion": "Preserve the original direction of lower pain at 24 hours with the selected formulation versus matching placebo, while separately recording uncertainty about placebo composition and sensory matching.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Composition, mass, capsule/taste/odor matching and actual allocated use of placebo in the relevant experiment. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The retained comparator is matching placebo. The original reader answer describes lower pain with raw ginger-powder capsules than placebo. Placebo composition and taste, odor or capsule-matching details are not provided.", "condition_status": "Partly verified", "status_reason": "The placebo comparison and direction are identified, while actual placebo specifications and sensory-matching verification remain unverified.", "missingness": "Placebo composition, mass, form, sensory matching and actual use remain unverified.", "uncertainty": "Placebo composition, mass, form, sensory matching and actual use remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Composition, mass, capsule/taste/odor matching and actual allocated use of placebo in the relevant experiment." }, { "item_id": "N09", "question_type": "Evidence condition", "question": "Which scale and procedures measured pain intensity at 24 hours for raw ginger-powder capsules?", "needed": "The original pain scale, range/direction, resting/movement/palpation conditions, assessor and assessment-time report.", "role": "Required", "role_reason": "Different scales, pain-provoking conditions or time points must not be combined as the same effect.", "application_exception": "The original designation of 24 hours as the principal endpoint is separate from verification of a preregistered primary endpoint.", "criterion": "Specify pain intensity 24 hours after eccentric elbow-flexor exercise, describing unverified scale, range, conditions and assessor details.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: The original pain scale, range/direction, resting/movement/palpation conditions, assessor and assessment-time report. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The retained principal endpoint is pain intensity 24 hours after eccentric elbow-flexor exercise, and the evidence endpoint is pain intensity 24 hours after exercise. The exact pain scale, setting and assessment range remain unverified in the retained material.", "condition_status": "Partly verified", "status_reason": "The endpoint type and selected time are identified, while measurement units and procedures remain insufficiently specified.", "missingness": "Pain-scale name, unit, range/direction, assessment setting and assessor details remain unverified.", "uncertainty": "Pain-scale name, unit, range/direction, assessment setting and assessor details remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "The original pain scale, range/direction, resting/movement/palpation conditions, assessor and assessment-time report." }, { "item_id": "N10", "question_type": "Evidence condition", "question": "Which measure, denominator and analysis do the raw ginger-powder capsule reports represent?", "needed": "Formulation-specific original pain results at 24 hours, absolute means/variances, percentage denominator/calculation, the definition of the SD label and CI/analysis tables.", "role": "Required", "role_reason": "The two formulations' 25%/23%, SD and P must not be exchanged or interpreted as direct formulation superiority.", "application_exception": "Do not rename SD as SMD without evidence, combine percentages with SD, or subtract another formulation's value.", "criterion": "Preserve 25%, −0.78 SD, P=.041 as the original report for this formulation versus placebo. Do not fill in formal percentage/SD measures, calculation, absolute units or CI.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Formulation-specific original pain results at 24 hours, absolute means/variances, percentage denominator/calculation, the definition of the SD label and CI/analysis tables. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original report attributed to raw ginger-powder capsules is 25%, −0.78 SD, P=.041. The complete result also retains the other formulation's 23%, −0.57 SD, P=.049. The exact percentage denominator, formal SD measure, analysis population and CI remain unverified.", "condition_status": "Partly verified", "status_reason": "Attribution of the selected formulation's numbers, sign and P to the placebo comparison is verified, while calculation, precision and analysis definitions remain unverified.", "missingness": "Absolute units, means/variances, percentage calculation/denominator, SD definition, CI and analysis population remain unverified; no new comparative effect is calculated.", "uncertainty": "Absolute units, means/variances, percentage calculation/denominator, SD definition, CI and analysis population remain unverified; no new comparative effect is calculated.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Formulation-specific original pain results at 24 hours, absolute means/variances, percentage denominator/calculation, the definition of the SD label and CI/analysis tables." }, { "item_id": "N11", "question_type": "Evidence condition", "question": "Among the samples of 34 and 40, what are the randomized, analyzed and completed denominators for raw ginger-powder capsules?", "needed": "Formulation-specific CONSORT flow, randomized/measured/analyzed/completed counts, withdrawal reasons and handling, and original result CI.", "role": "Required", "role_reason": "Do not fill the selected effect's sample basis and precision using another formulation's sample or a completed-participant count.", "application_exception": "Do not assign 34 to raw and 40 to heat-treated powder from source order, or generate a total, equal arm split or ITT population.", "criterion": "Retain the original samples of 34 and 40, distinguishing unverified formulation mapping, per-arm randomized/analyzed/completed/missing counts and CI.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Formulation-specific CONSORT flow, randomized/measured/analyzed/completed counts, withdrawal reasons and handling, and original result CI. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The evidence sample-size field reports ‘34 and 40’, and the retained population also reports 34 and 40. Which sample belongs to raw or heat-treated powder, and whether it represents randomization, analysis or completion, is not specified by formulation.", "condition_status": "Partly verified", "status_reason": "The two reported sample-size strings are identified, while selected formulation/per-arm stages and missingness denominators remain unverified.", "missingness": "Formulation mapping to 34/40, per-arm counts, analysis/completion, missingness/withdrawals, ITT/PP and CI remain unverified.", "uncertainty": "Formulation mapping to 34/40, per-arm counts, analysis/completion, missingness/withdrawals, ITT/PP and CI remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Formulation-specific CONSORT flow, randomized/measured/analyzed/completed counts, withdrawal reasons and handling, and original result CI." }, { "item_id": "N12", "question_type": "Evidence condition", "question": "What are the evidence date and actual verification scope of this raw ginger-powder capsule conversion?", "needed": "The retained review date, current input identity, actual actions in this work and later authorized search/correction/retraction-check records.", "role": "Required", "role_reason": "The retained-summary conversion must not be presented as a current complete literature or registration search.", "application_exception": "No search in this work does not mean 0 studies. A historical verdict date is not inherited as a current external-access date.", "criterion": "Distinguish the original verdict date from this review date, accurately recording that new searching, retraction/correction and registration checks were not performed.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: The retained review date, current input identity, actual actions in this work and later authorized search/correction/retraction-check records. This records needed materials; no new research was executed.", "current_reports": [ "S01", "S02" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original verdict date is 2026-09-08, and the correction record describes English evidence-table wording changes on 2026-09-14. This converts the fixed retained summary without new clinical searching, abstract/full-text reading, registration review or retraction checks.", "condition_status": "Met", "status_reason": "Met applies to separating the retained evidence date from the actual material scope in this work.", "missingness": "Current existence and content of additional studies, retractions/corrections, unpublished material or registration after the retained date remain unverified.", "uncertainty": "Current existence and content of additional studies, retractions/corrections, unpublished material or registration after the retained date remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "The retained review date, current input identity, actual actions in this work and later authorized search/correction/retraction-check records." }, { "item_id": "N13", "question_type": "Evidence condition", "question": "How much is verified about funding, product support and author interests in the raw ginger-powder capsule experiments?", "needed": "Original funding, product-support, author-role/employment, patent and COI statements, with institutional/family links.", "role": "Supplementary; required for independence claims", "role_reason": "Recorded support must not automatically exclude the result or turn another formulation's result into independent funding or independent-team replication.", "application_exception": "Preserve the historical description of industry support without assigning a new bias grade or an exact bias magnitude.", "criterion": "Retain McCormick Science Institute support and the same-team relationship, separately recording unverified product support, employment, patents and declared COI.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Original funding, product-support, author-role/employment, patent and COI statements, with institutional/family links. This records needed materials; no new research was executed.", "current_reports": [ "S01", "S02" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "S01 records research funding from the McCormick Science Institute and two experiments by the same team. Product support, employment/patents and declared COI details remain unverified, as do product/funding details for S02.", "condition_status": "Partly verified", "status_reason": "The stated funding/team relationship is identified, while original interest-specific statements and further independence details remain unverified.", "missingness": "S01 product support, author employment/roles, patents and COI details, and S02 funding/product details remain unverified.", "uncertainty": "S01 product support, author employment/roles, patents and COI details, and S02 funding/product details remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Original funding, product-support, author-role/employment, patent and COI statements, with institutional/family links." }, { "item_id": "N14", "question_type": "Evidence condition", "question": "What were the actual allocation and concealment procedures for raw ginger-powder capsules versus placebo?", "needed": "Group structure, sequence generation, concealment, baseline balance and implementation records for the selected experiment.", "role": "Required", "role_reason": "An RCT label alone must not be taken to resolve allocation or confounding issues.", "application_exception": "Do not inherit the S02 crossover design into S01 or automatically fill in parallel/crossover details for S01 while they remain unverified.", "criterion": "Distinguish the recorded randomized, double-blind, placebo-controlled design from unverified formulation-specific design, sequence generation, concealment and baseline tables.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Group structure, sequence generation, concealment, baseline balance and implementation records for the selected experiment. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "S01 is recorded as 2 randomized, double-blind, placebo-controlled experiments by the same team. Sequence generation, concealment, group-structure details and baseline balance for the selected formulation are not verified in the local summary.", "condition_status": "Partly verified", "status_reason": "The randomized/blinded/placebo design label is identified, while actual allocation implementation remains unverified.", "missingness": "Formulation-specific group structure, sequence generation, concealment, baseline imbalance and implementation records remain unverified.", "uncertainty": "Formulation-specific group structure, sequence generation, concealment, baseline imbalance and implementation records remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Group structure, sequence generation, concealment, baseline balance and implementation records for the selected experiment." }, { "item_id": "N15", "question_type": "Evidence condition", "question": "Can adherence, co-interventions and rescue-analgesic differences between raw ginger-powder capsule and placebo groups be distinguished?", "needed": "Per-arm dosing adherence, exercise implementation, diet/other supplements, rescue analgesics, changes/deviations and their analytical handling.", "role": "Required", "role_reason": "Differences in concurrent treatment or exercise workload must not be attributed to the powder effect.", "application_exception": "Missing information does not mean co-interventions/rescue treatments were absent or identical between arms.", "criterion": "Link actual formulation-specific dosing/exercise adherence, co-interventions/analgesics and deviation handling to observed pain.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Per-arm dosing adherence, exercise implementation, diet/other supplements, rescue analgesics, changes/deviations and their analytical handling. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The 2 g/day, 11-day regimen and placebo comparison are recorded, but specific information about actual adherence, concomitant medicines, rescue analgesics, exercise deviations and their handling for this formulation is not verified in the retained summary.", "condition_status": "Unverified", "status_reason": "Actual per-arm use, concurrent interventions and changes are unavailable, so conformity with this condition cannot be determined.", "missingness": "Adherence, co-interventions, rescue analgesics, exercise-workload changes, deviations and their analytical impact remain unverified.", "uncertainty": "Adherence, co-interventions, rescue analgesics, exercise-workload changes, deviations and their analytical impact remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Per-arm dosing adherence, exercise implementation, diet/other supplements, rescue analgesics, changes/deviations and their analytical handling." }, { "item_id": "N16", "question_type": "Evidence condition", "question": "Who was blinded during subjective pain assessment for raw ginger-powder capsules, and were sensory differences checked?", "needed": "Participant/assessor/analyst blinding by role, taste/odor/capsule differences, blinding assessment and measurement procedures.", "role": "Required", "role_reason": "Expectancy and measurement differences can affect interpretation of subjective pain, so the actual blinded roles need to be identified.", "application_exception": "Unverified blinding is not confirmed blinding failure, and a matching-placebo label does not replace a success assessment.", "criterion": "Distinguish the double-blind label from actual verification of participant/assessor roles, sensory matching and blinding success.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Participant/assessor/analyst blinding by role, taste/odor/capsule differences, blinding assessment and measurement procedures. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "S01 is labelled double-blind with matching placebo. Who was blinded, sensory-matching verification, assessor/analyst conditions and blinding-success assessment remain unverified in the retained material.", "condition_status": "Partly verified", "status_reason": "The blinding label is identified, while roles and implementation directly relevant to pain measurement remain unverified.", "missingness": "Role-specific blinding, sensory matching/success assessment and pain assessor/procedure details remain unverified.", "uncertainty": "Role-specific blinding, sensory matching/success assessment and pain assessor/procedure details remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Participant/assessor/analyst blinding by role, taste/odor/capsule differences, blinding assessment and measurement procedures." }, { "item_id": "N17", "question_type": "Evidence condition", "question": "Does the reported raw ginger-powder capsule effect represent an assignment effect or an adherence effect?", "needed": "Planned/actual analysis populations, ITT/PP definitions, formulation-specific models, adjustment, repeated measures and original missing-data handling tables.", "role": "Required", "role_reason": "Even the same P value must not transfer results from different analyses or populations as the same effect.", "application_exception": "Generic English denominator/result wording that mentions separation or verification does not establish actual ITT or model verification.", "criterion": "Specify ITT/PP, analysis population, repeated-measures/between-group comparisons and adjustment/missing-data handling only to the extent verified, retaining unknowns.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Planned/actual analysis populations, ITT/PP definitions, formulation-specific models, adjustment, repeated measures and original missing-data handling tables. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The 25%, −0.78 SD, P=.041 report concerns lower pain with the selected formulation than placebo. Analysis population, ITT/PP, assignment/adherence effect, repeated-measures model, adjustment and missing-data handling details remain unverified.", "condition_status": "Unverified", "status_reason": "The effect report is retained, while the effect of interest and analysis definition are not specified by the current input.", "missingness": "ITT/PP, analysis population/model, repeated measures, adjustment, missing-data handling and the exact estimand remain unverified.", "uncertainty": "ITT/PP, analysis population/model, repeated measures, adjustment, missing-data handling and the exact estimand remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Planned/actual analysis populations, ITT/PP definitions, formulation-specific models, adjustment, repeated measures and original missing-data handling tables." }, { "item_id": "N18", "question_type": "Evidence condition", "question": "Can uncertainty and importance of the raw ginger-powder capsule pain difference at 24 hours be assessed?", "needed": "Formulation-specific effect CI, scale-specific variance, analysis denominator, MID/important-difference evidence and the effect definition.", "role": "Required", "role_reason": "A significant P, an SD label or a description of a small sample must not create a new sufficiency/precision verdict.", "application_exception": "Do not impose common minimum participant, trial or duration thresholds, or recalculate CI from SD/P.", "criterion": "Relate precision and importance only when verified CI, variance and justified important-difference criteria are available. Do not determine sufficiency from P or a historical effect-size description.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Formulation-specific effect CI, scale-specific variance, analysis denominator, MID/important-difference evidence and the effect definition. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "Raw ginger-powder capsules are reported as 25%, −0.78 SD, P=.041, but CI, scale-specific MID and absolute pain differences are absent from the retained summary. The original explanation/grade historically describes a moderate-or-larger effect exceeding its threshold; this review does not newly certify that assessment.", "condition_status": "Unverified", "status_reason": "Material directly comparing CI, the effect definition and important-difference criteria remains unverified.", "missingness": "CI, variance/units, MID, important-difference criteria/evidence and formulation-specific denominators remain unverified.", "uncertainty": "CI, variance/units, MID, important-difference criteria/evidence and formulation-specific denominators remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Formulation-specific effect CI, scale-specific variance, analysis denominator, MID/important-difference evidence and the effect definition." }, { "item_id": "N19", "question_type": "Evidence condition", "question": "Were the raw ginger-powder capsule endpoint at 24 hours and its analysis specified in advance?", "needed": "Exact trial registration, prospective protocol/SAP, endpoint/time/formulation testing hierarchy, multiplicity handling and reasons for changes.", "role": "Required", "role_reason": "The information gap needed to examine favorable time-point or analysis selection must remain visible.", "application_exception": "Unidentified registration is not proof of an unregistered trial. PMID/DOI does not replace registration/SAP verification.", "criterion": "Confirm only portions actually compared between registration/protocol/SAP and reporting. Do not inherit the principal-endpoint field or P axis as confirmation of prospective planning.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Exact trial registration, prospective protocol/SAP, endpoint/time/formulation testing hierarchy, multiplicity handling and reasons for changes. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The retained principal-endpoint field and endpoint axis P are historical labels. Registration is recorded as unidentified; the prospective 24-hour hierarchy, SAP and corrections for multiple time points/formulation tests have not been verified in this work.", "condition_status": "Unverified", "status_reason": "No planning-versus-reporting comparison is available, so consistency of planned endpoints and analyses remains unverified.", "missingness": "Registration identity, prospective registration date, protocol/SAP, the prospective primary endpoint at 24 hours, multiplicity and reasons for changes remain unverified.", "uncertainty": "Registration identity, prospective registration date, protocol/SAP, the prospective primary endpoint at 24 hours, multiplicity and reasons for changes remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Exact trial registration, prospective protocol/SAP, endpoint/time/formulation testing hierarchy, multiplicity handling and reasons for changes." }, { "item_id": "N20", "question_type": "Evidence condition", "question": "Can the heat-treated ginger-powder capsule result be read as independent reproduction of raw ginger-powder capsules or a superiority comparison?", "needed": "Formulation-specific experiment regimens, direct head-to-head analyses and direct evidence for the same formulation from other teams.", "role": "Required", "role_reason": "Creating two sheets or having two different numbers does not establish independent replication or heat-treated superiority.", "application_exception": "Do not subtract the two values to establish superiority or equivalence. Whether the original paper reported a direct comparison has not been verified in this work.", "criterion": "Retain the other formulation's placebo comparison in the same paper/team as context, without adding it as independent-team direct replication of the selected formulation or a direct between-formulation effect.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Formulation-specific experiment regimens, direct head-to-head analyses and direct evidence for the same formulation from other teams. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The selected raw ginger-powder capsule report is 25%, −0.78 SD, P=.041; the heat-treated ginger-powder capsule report in the same S01 is 23%, −0.57 SD, P=.049. The central explanation describes two experiments in the same team/paper, and the advertising boundary does not permit a heat-treated superiority claim.", "condition_status": "Met", "status_reason": "Met applies to distinguishing verified formulation/team/report boundaries and limiting overinterpretation of replication or superiority.", "missingness": "Direct same-formulation replication by other teams, direct comparison of the two formulations and unique-participant/experiment details remain unverified.", "uncertainty": "Direct same-formulation replication by other teams, direct comparison of the two formulations and unique-participant/experiment details remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Formulation-specific experiment regimens, direct head-to-head analyses and direct evidence for the same formulation from other teams." }, { "item_id": "N21", "question_type": "Evidence condition", "question": "How does the single 2 g crossover trial S02 relate to the raw ginger-powder capsule, 11-day question?", "needed": "The exact S02 formulation, dosing/exercise timing, washout/periods, pain time points, analysis/CI and participant flow.", "role": "Required", "role_reason": "The unfavorable observation must be retained while avoiding mixing a different regimen into direct replication of the selected formulation.", "application_exception": "Do not infer the 25 people as each period's denominator, completers or formulation-specific counts. Retain the Korean immediately-before and English around wording without inventing harmonized exact timing.", "criterion": "Retain the single/repeated dosing, timing and endpoint differences and the negative observation. Do not turn them into proof of no effect/equivalence or conflicting results under the same regimen.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: The exact S02 formulation, dosing/exercise timing, washout/periods, pain time points, analysis/CI and participant flow. This records needed materials; no new research was executed.", "current_reports": [ "S01", "S02" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "S02 is a randomized, placebo-controlled crossover trial reporting 25 people and no clinically/statistically meaningful effect with a single 2 g dose. The Korean text says immediately before exercise, while the English says immediately around exercise. It is retained as a different regimen from 11-day repeated dosing.", "condition_status": "Partly verified", "status_reason": "The separate report's negative observation and single-dose crossover regimen are identified, while actual formulation, timing, periods, analysis and interval estimates remain unverified.", "missingness": "S02 formulation, exact timing, washout/periods, assessment times, denominator stages, CI/equivalence criteria remain unverified; effect 0 is not established.", "uncertainty": "S02 formulation, exact timing, washout/periods, assessment times, denominator stages, CI/equivalence criteria remain unverified; effect 0 is not established.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "The exact S02 formulation, dosing/exercise timing, washout/periods, pain time points, analysis/CI and participant flow." }, { "item_id": "N22", "question_type": "Evidence condition", "question": "Must this 24-hour question also establish the optimal dose of raw ginger-powder capsules?", "needed": "Direct formulation-specific dose comparisons and analysis/safety material, distinguished from material required for the current narrow regimen.", "role": "Supplementary; required for the relevant extension question", "role_reason": "Do not automatically append an optimal-dose claim; retain the review scope of the selected 24-hour result.", "application_exception": "Not applicable applies only to the obligation to require extension research as a prerequisite for the current result. Direct evidence remains unverified.", "criterion": "Do not require proof of an optimal dose as mandatory for the narrow 24-hour, healthy-adult, 2 g/day for 11 days question. Separately retain that the relevant material remains unverified.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Direct formulation-specific dose comparisons and analysis/safety material, distinguished from material required for the current narrow regimen. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The selected question is raw ginger-powder capsules, 2 g/day for 11 days, versus matching placebo for pain intensity 24 hours after eccentric elbow-flexor exercise. A direct optimal-dose estimate remains unverified in the retained material, and that extension is not added to the original claim.", "condition_status": "Not applicable", "status_reason": "The obligation to require optimal-dose proof for the narrow question does not apply. This does not mean the material is unnecessary, absent or proof of no effect.", "missingness": "Direct optimal-dose evidence and estimates remain unverified; separate mandatory review would apply if the scope is extended.", "uncertainty": "Direct optimal-dose evidence and estimates remain unverified; separate mandatory review would apply if the scope is extended.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Direct formulation-specific dose comparisons and analysis/safety material, distinguished from material required for the current narrow regimen." }, { "item_id": "N23", "question_type": "Evidence condition", "question": "Must this question also establish long-term pain effects after stopping raw ginger-powder capsules?", "needed": "Post-discontinuation/long-term follow-up, exposure logs, time-specific pain estimates and missing-data material, distinguished from material required for the current narrow regimen.", "role": "Supplementary; required for the relevant extension question", "role_reason": "Do not automatically append a persistence-after-stopping claim; retain the review scope of the selected 24-hour result.", "application_exception": "Not applicable applies only to the obligation to require extension research as a prerequisite for the current result. Direct evidence remains unverified.", "criterion": "Do not require proof of persistence after stopping as mandatory for the narrow 24-hour, healthy-adult, 2 g/day for 11 days question. Separately retain that the relevant material remains unverified.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Post-discontinuation/long-term follow-up, exposure logs, time-specific pain estimates and missing-data material, distinguished from material required for the current narrow regimen. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The selected question is raw ginger-powder capsules, 2 g/day for 11 days, versus matching placebo for pain intensity 24 hours after eccentric elbow-flexor exercise. A direct estimate of persistence after stopping remains unverified in the retained material, and that extension is not added to the original claim.", "condition_status": "Not applicable", "status_reason": "The obligation to require proof of persistence after stopping for the narrow question does not apply. This does not mean the material is unnecessary, absent or proof of no effect.", "missingness": "Direct evidence and estimates of persistence after stopping remain unverified; separate mandatory review would apply if the scope is extended.", "uncertainty": "Direct evidence and estimates of persistence after stopping remain unverified; separate mandatory review would apply if the scope is extended.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Post-discontinuation/long-term follow-up, exposure logs, time-specific pain estimates and missing-data material, distinguished from material required for the current narrow regimen." }, { "item_id": "N24", "question_type": "Evidence condition", "question": "Must this question also establish raw ginger-powder capsule effects in particular age or training subgroups?", "needed": "Prospective subgroup plans, composition/denominators, interaction tests and direct estimates, distinguished from material required for the current narrow regimen.", "role": "Supplementary; required for the relevant extension question", "role_reason": "Do not automatically append a particular-subgroup claim; retain the review scope of the selected 24-hour result.", "application_exception": "Not applicable applies only to the obligation to require extension research as a prerequisite for the current result. Direct evidence remains unverified.", "criterion": "Do not require proof of particular subgroup effects as mandatory for the narrow 24-hour, healthy-adult, 2 g/day for 11 days question. Separately retain that the relevant material remains unverified.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Prospective subgroup plans, composition/denominators, interaction tests and direct estimates, distinguished from material required for the current narrow regimen. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The selected question is raw ginger-powder capsules, 2 g/day for 11 days, versus matching placebo for pain intensity 24 hours after eccentric elbow-flexor exercise. Direct estimates for particular subgroups remain unverified in the retained material, and that extension is not added to the original claim.", "condition_status": "Not applicable", "status_reason": "The obligation to require proof of particular subgroup effects for the narrow question does not apply. This does not mean the material is unnecessary, absent or proof of no effect.", "missingness": "Direct subgroup evidence and estimates remain unverified; separate mandatory review would apply if the scope is extended.", "uncertainty": "Direct subgroup evidence and estimates remain unverified; separate mandatory review would apply if the scope is extended.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Prospective subgroup plans, composition/denominators, interaction tests and direct estimates, distinguished from material required for the current narrow regimen." }, { "item_id": "N25", "question_type": "Evidence condition", "question": "Is the raw ginger-powder capsule pain result at 24 hours extended into guaranteed recovery or prevention of muscle injury?", "needed": "Direct clinical endpoints, duration/denominators, comparisons and precision if recovery or injury prevention is claimed.", "role": "Supplementary; required for extension to recovery or injury prevention", "role_reason": "A symptom difference must not automatically be promoted to other functions, events or guarantees.", "application_exception": "Not applicable applies only to the obligation to prove a separate clinical extension. Unverified recovery/prevention material is not changed into evidence of no effect.", "criterion": "Distinguish pain intensity itself from the clinical questions of exercise recovery/injury prevention. Do not require a separate event trial as mandatory for the narrow pain result.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Direct clinical endpoints, duration/denominators, comparisons and precision if recovery or injury prevention is claimed. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The selected endpoint is pain intensity at 24 hours. The advertising boundary does not permit guaranteed exercise recovery or prevention of muscle injury and keeps other time points, strength, ROM and CK separate.", "condition_status": "Not applicable", "status_reason": "The obligation to require recovery/injury-prevention proof for the narrow pain question does not apply, while direct clinical-extension evidence remains unverified.", "missingness": "Direct clinical outcomes, denominators/duration and estimates for guaranteed recovery or injury prevention remain unverified.", "uncertainty": "Direct clinical outcomes, denominators/duration and estimates for guaranteed recovery or injury prevention remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Direct clinical endpoints, duration/denominators, comparisons and precision if recovery or injury prevention is claimed." }, { "item_id": "N26", "question_type": "Evidence condition", "question": "Which adverse events were collected, and how, in the raw ginger-powder capsule experiment?", "needed": "Formulation-specific original AE definitions, systematic/spontaneous collection, diagnosis/severity and discontinuation tables and protocol.", "role": "Supplementary; required for harm or safety questions", "role_reason": "An efficacy summary or general caution must not replace actual event counts or establish safety.", "application_exception": "Unverified information in the summary does not establish nonreporting throughout the original paper. Insufficient harm verification is not a reason to delete the retained efficacy report.", "criterion": "Distinguish original caution wording from actual AE definitions, collection, severity and discontinuation in the relevant experiment. Do not infer that events were absent.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Formulation-specific original AE definitions, systematic/spontaneous collection, diagnosis/severity and discontinuation tables and protocol. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original safety label is Caution, with advice to consider gastrointestinal discomfort and medicine interactions. Actual AE definitions, collection methods, events/severity and discontinuation records for the selected formulation remain unverified in the retained summary.", "condition_status": "Unverified", "status_reason": "Direct information verifying actual harm observations and collection scope for this formulation is unavailable.", "missingness": "AE definitions, collection method, events/severity, diagnosis, discontinuation and recovery remain unverified.", "uncertainty": "AE definitions, collection method, events/severity, diagnosis, discontinuation and recovery remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Formulation-specific original AE definitions, systematic/spontaneous collection, diagnosis/severity and discontinuation tables and protocol." }, { "item_id": "N27", "question_type": "Evidence condition", "question": "Is the timing of raw ginger-powder capsule exposure, harm onset, stopping and recovery verified?", "needed": "Individual AE onset/recovery times, dosing logs, stopping/rechallenge and follow-up duration.", "role": "Supplementary; required for harm timing or causality", "role_reason": "The efficacy regimen of 11 days of dosing and 3 days of follow-up must not be converted into a complete harm timeline.", "application_exception": "No event record does not mean latency, stopping or rechallenge did not occur.", "criterion": "Distinguish dosing duration from actual event onset/latency, stopping, recovery and rechallenge. Temporal sequence alone does not establish causality.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Individual AE onset/recovery times, dosing logs, stopping/rechallenge and follow-up duration. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The 11-day dosing and 3-day postexercise follow-up are recorded, but actual harm onset, stopping, recovery or rechallenge timelines are not linked in the retained summary.", "condition_status": "Unverified", "status_reason": "Efficacy dosing/follow-up time cannot substitute for the temporal sequence of an event.", "missingness": "Event latency, onset/recovery, stopping, rechallenge and safety follow-up time remain unverified.", "uncertainty": "Event latency, onset/recovery, stopping, rechallenge and safety follow-up time remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Individual AE onset/recovery times, dosing logs, stopping/rechallenge and follow-up duration." }, { "item_id": "N28", "question_type": "Evidence condition", "question": "Were adverse-event differences between raw ginger-powder capsules and placebo directly compared?", "needed": "Actual AE people/event counts, collection periods/methods, between-group estimates and CI for formulation/placebo arms.", "role": "Supplementary; required for comparative harms", "role_reason": "The placebo-controlled efficacy label must not be inherited as verification of a harm comparison.", "application_exception": "The comparator may be known while harm tables remain unverified. Do not fill them with external background incidence.", "criterion": "Separate the efficacy placebo comparison from actual per-arm harm collection/estimation. Do not infer risk differences or incidence.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Actual AE people/event counts, collection periods/methods, between-group estimates and CI for formulation/placebo arms. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "A matching-placebo efficacy comparison is recorded, but actual between-group adverse-event comparisons, differences and CI remain unverified in the current retained summary.", "condition_status": "Unverified", "status_reason": "Actual comparative harm results could not be examined.", "missingness": "Formulation/placebo AE events, collection periods/methods and comparative estimates/CI remain unverified.", "uncertainty": "Formulation/placebo AE events, collection periods/methods and comparative estimates/CI remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Actual AE people/event counts, collection periods/methods, between-group estimates and CI for formulation/placebo arms." }, { "item_id": "N29", "question_type": "Evidence condition", "question": "Are there exposure denominators and event counts to calculate harm frequency for raw ginger-powder capsules?", "needed": "Formulation-specific exposure/safety-analysis counts, AE people and event counts, exposure time, follow-up losses and recruitment/reporting systems.", "role": "Supplementary; required for harm frequency", "role_reason": "Reported trial sample sizes must not be misread as incidence denominators.", "application_exception": "Do not use the 34/40 samples, whose efficacy mapping is itself unverified, as incidence denominators or add the single-dose trial's 25 people.", "criterion": "Use only reports linking formulation-specific exposure/safety-analysis denominators, people/event counts and time. Do not inherit 34/40 as harm denominators.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Formulation-specific exposure/safety-analysis counts, AE people and event counts, exposure time, follow-up losses and recruitment/reporting systems. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original samples of 34 and 40 are experiment sample-size strings with formulation mapping and denominator stages unverified. Actual people/event counts, formulation-specific exposure denominators and safety follow-up times are also unavailable.", "condition_status": "Unverified", "status_reason": "The numerator, exposure denominator and time are not linked, so direct harm frequency cannot be verified.", "missingness": "AE people/event counts, formulation/per-arm exposure or safety-analysis denominators and time remain unverified; no incidence is calculated.", "uncertainty": "AE people/event counts, formulation/per-arm exposure or safety-analysis denominators and time remain unverified; no incidence is calculated.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Formulation-specific exposure/safety-analysis counts, AE people and event counts, exposure time, follow-up losses and recruitment/reporting systems." }, { "item_id": "N30", "question_type": "Evidence condition", "question": "Are concomitant medicines, baseline conditions and other exposures that might explain harms with raw ginger-powder capsules verified?", "needed": "Concomitant medicines/supplements, baseline GI conditions, exercise workload/lifestyle exposures, alternative-explanation assessment and adjustment material.", "role": "Supplementary; required for causal or comparative harms", "role_reason": "A general interaction caution must not be turned into an observed trial interaction or attribution to one exposure.", "application_exception": "Unverified alternatives do not mean no alternative cause existed. Do not generate personal dosing instructions.", "criterion": "Attribute harms only to the extent actual concurrent exposures, baseline symptoms and alternative explanations/adjustment have been verified.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Concomitant medicines/supplements, baseline GI conditions, exercise workload/lifestyle exposures, alternative-explanation assessment and adjustment material. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original text explicitly advises consideration of medicine interactions. Actual concomitant medicines, baseline symptoms, alternative explanations and adjustment in the relevant experiment remain unverified in the current summary.", "condition_status": "Unverified", "status_reason": "General caution alone cannot establish actual concurrent exposures or causal attribution within the trial.", "missingness": "Co-interventions, baseline conditions, concurrent exercise/other exposures, alternative assessment and adjustment remain unverified.", "uncertainty": "Co-interventions, baseline conditions, concurrent exercise/other exposures, alternative assessment and adjustment remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Concomitant medicines/supplements, baseline GI conditions, exercise workload/lifestyle exposures, alternative-explanation assessment and adjustment material." }, { "item_id": "N31", "question_type": "Evidence condition", "question": "What are the reporting selection, detection differences and follow-up losses in raw ginger-powder capsule harm material?", "needed": "AE collection tools, scope of complete event disclosure, per-arm detection/withdrawals and safety missing-data handling.", "role": "Supplementary; required for review of harm material", "role_reason": "Reporting a pain effect and completely reporting safety material are distinct facts.", "application_exception": "Unverified possible bias is not converted into a definite bias magnitude or invalidation of the result.", "criterion": "Verify collection/selection, disclosure of all events, per-arm detection and follow-up losses. Do not turn summary-level unknowns into absence of events.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: AE collection tools, scope of complete event disclosure, per-arm detection/withdrawals and safety missing-data handling. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The S01 summary records pain results but does not specify safety collection/selection, per-arm detection, follow-up losses or missing-data handling. This does not establish nonreporting throughout the complete paper.", "condition_status": "Unverified", "status_reason": "Direct selection, detection and missingness records could not be verified.", "missingness": "AE collection/disclosure scope, per-arm detection, withdrawals and safety missing-data handling remain unverified.", "uncertainty": "AE collection/disclosure scope, per-arm detection, withdrawals and safety missing-data handling remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "AE collection tools, scope of complete event disclosure, per-arm detection/withdrawals and safety missing-data handling." }, { "item_id": "N32", "question_type": "Evidence condition", "question": "Was the same harm with raw ginger-powder capsules recorded in other independent material?", "needed": "Actual harm source material for the selected formulation, event/study families, independence/re-citation and contrary records.", "role": "Supplementary; required for repeated-harm claims", "role_reason": "Two same-team pain experiments or two sheets must not be counted as independent safety replication.", "application_exception": "No new harm search is performed in this work. Unverified material is not changed into 0 replications or no events.", "criterion": "Link actual event/harm-study families, re-citation and exposure matching only to the extent verified. Do not count pain experiments as harm replications.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Actual harm source material for the selected formulation, event/study families, independence/re-citation and contrary records. This records needed materials; no new research was executed.", "current_reports": [ "S01", "S02" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original record distinguishes two efficacy experiments by the same team from a single-dose crossover trial. Material verifying actual same-harm families or independent repetition for the selected formulation remains unverified in the current summary.", "condition_status": "Unverified", "status_reason": "Relationships between efficacy-report families alone cannot verify actual harm-replication relationships.", "missingness": "Original harm material, event identity/overlap, independent families and contrary records remain unverified.", "uncertainty": "Original harm material, event identity/overlap, independent families and contrary records remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Actual harm source material for the selected formulation, event/study families, independence/re-citation and contrary records." }, { "item_id": "N33", "question_type": "Evidence condition", "question": "Must a short-term healthy-adult pain question about raw ginger-powder capsules require proof of all long-term, rare and vulnerable-population harms?", "needed": "Direct long-term exposure, rare-event, vulnerable-population/interaction material and suitable designs if the harm scope is extended.", "role": "Supplementary; required for long-term or vulnerable-population harm questions", "role_reason": "Short-term efficacy material must not be turned into overall safety or make all extension research mandatory for the current pain sheet.", "application_exception": "Not applicable applies only to the extension-proof obligation. Direct long-term, rare and vulnerable-population information remains unverified, and general caution is retained.", "criterion": "Do not require proof of every long-term, rare or vulnerable-population harm to prepare the current narrow efficacy question, while retaining the unverified status of that direct information.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Direct long-term exposure, rare-event, vulnerable-population/interaction material and suitable designs if the harm scope is extended. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The current question is limited to healthy adults, 11-day repeated dosing and pain at 24 hours. The original caution is retained, while direct information on long-term, rare and vulnerable-population harms remains unverified.", "condition_status": "Not applicable", "status_reason": "The obligation to require every extended safety proof for this narrow pain sheet does not apply. This is not safety certification.", "missingness": "Direct long-term/rare-event harm material and vulnerable-population material concerning pregnancy, disease or concomitant medicines remain unverified.", "uncertainty": "Direct long-term/rare-event harm material and vulnerable-population material concerning pregnancy, disease or concomitant medicines remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Direct long-term exposure, rare-event, vulnerable-population/interaction material and suitable designs if the harm scope is extended." }, { "item_id": "N34", "question_type": "Evidence condition", "question": "Is the original raw ginger-powder capsule caution wording being turned into incidence, causal attribution or safety certification?", "needed": "Design, comparison, denominator, time and alternative explanations in original harm material, and the attribution/interpretive scope of caution wording.", "role": "Supplementary; required for harm interpretation", "role_reason": "General caution must not be promoted into confirmed experimental AEs or a safety grade.", "application_exception": "This retained-summary conversion is not execution of a causality tool, a new safety verdict or dosing instructions. Uncertain cautions are not deleted.", "criterion": "Separate the historical parent C50/Caution wording from unverified actual harm observations. Do not create personal dosing instructions or determinate incidence/causal claims.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Design, comparison, denominator, time and alternative explanations in original harm material, and the attribution/interpretive scope of caution wording. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original safety label is Caution, retaining gastrointestinal discomfort, consideration of medicine interactions and the warning against replacing exercise-injury treatment. Actual events, denominators/time and causality remain unverified. No new formulation-specific safety or efficacy grade is created.", "condition_status": "Partly verified", "status_reason": "The original caution and its interpretive limits are identified, while actual harm reporting, comparison and causal content remain unverified.", "missingness": "Direct harm signals, comparative risks, events, denominators/time and causal evidence remain unverified; caution is historically preserved.", "uncertainty": "Direct harm signals, comparative risks, events, denominators/time and causal evidence remain unverified; caution is historically preserved.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Design, comparison, denominator, time and alternative explanations in original harm material, and the attribution/interpretive scope of caution wording." }, { "item_id": "N35", "question_type": "Evidence condition", "question": "Does the raw ginger-powder capsule sheet preserve the original Korean/English text, C50, axes, corrections and empty/unverified value types?", "needed": "The complete current original and source identity, Korean/English text and axes, evidence/bibliography, corrections and typed equality of original empty values.", "role": "Required", "role_reason": "Track that conversion into formulation-specific sheets does not newly modify the original verdict, English placeholder correction or historical grade.", "application_exception": "The correction describes specific replacement of 2 fields, while generic wording remains in the current English evidence table. Preserve both without reading them as actual denominator, funding or CI verification.", "criterion": "Preserve the complete current original with its types. Do not automatically inherit generic English wording, original corrections, scores or axes as evidence of new verification or a new verdict.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: The complete current original and source identity, Korean/English text and axes, evidence/bibliography, corrections and typed equality of original empty values. This records needed materials; no new research was executed.", "current_reports": [ "S01", "S02" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original C50, Caution, B/P/R1/I0/E+/B2/C0, all booleans, empty strings/original arrays, Korean/English text and 2026-09-14 correction record are retained unchanged. Generic original English wording about denominator, funding and result verification does not replace actual verification material.", "condition_status": "Met", "status_reason": "Met applies to actual whole-record comparison of current values, types and historical/current distinctions. It is not new clinical certification of the original verdict.", "missingness": "Actual specific verification evidence behind generic English wording and the original full paper remain unverified; no new formulation-specific score/grade is assigned.", "uncertainty": "Actual specific verification evidence behind generic English wording and the original full paper remain unverified; no new formulation-specific score/grade is assigned.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "The complete current original and source identity, Korean/English text and axes, evidence/bibliography, corrections and typed equality of original empty values." }, { "item_id": "N36", "question_type": "Evidence condition", "question": "Is the raw ginger-powder capsule pain result at 24 hours combined with 48/72-hour pain, strength, ROM or CK?", "needed": "Original tables of time-specific pain, strength/ROM/CK and inflammatory-marker definitions, prospective hierarchy, denominators, analysis and CI.", "role": "Required", "role_reason": "A favorable 24-hour value must not make every other endpoint successful or turn separate handling into a statement of failure.", "application_exception": "Other endpoints are retained with separate scope. The original explanation/scope note says to treat them separately; it does not explicitly report each result as 0 or nonsignificant.", "criterion": "Keep selected 24-hour pain distinct from other times, functions and markers. Do not create individual values or determinate success/failure results not supplied by the original record.", "basis": "Existing method principles distinguish population, formulation, dose, timing, endpoint, comparison, denominators, overlap, support and harms in the retained reports. Detailed conditions are Chamgap's own application.", "condition_origin": "These are Chamgap in-house conditions developed with knowledge of the retained record for raw ginger powder, healthy adults, pain after eccentric exercise and matching placebo. They do not establish blinding, clinical-trial preregistration, official-tool certification, new independent clinical validation or a new formulation-specific grade.", "proposed_research": "Material needed: Original tables of time-specific pain, strength/ROM/CK and inflammatory-marker definitions, prospective hierarchy, denominators, analysis and CI. This records needed materials; no new research was executed.", "current_reports": [ "S01" ], "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified.", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "observation": "The original explanation says 48- and 72-hour outcomes, strength, ROM and inflammatory markers were not combined into the same success. The scope note keeps other time points, strength, ROM and CK separate. Individual values, CI and hierarchy remain unverified in the current material.", "condition_status": "Met", "status_reason": "Met applies to retaining the verified endpoint/time limits and avoiding aggregation. It does not establish success or failure of other outcomes.", "missingness": "Direct values, denominators, analyses/CI and prospective hierarchy for each other endpoint/time remain unverified.", "uncertainty": "Direct values, denominators, analyses/CI and prospective hierarchy for each other endpoint/time remain unverified.", "review_date": "2026-10-06", "reading_status": "Full text not read · Stored summary read", "additional_material": "Original tables of time-specific pain, strength/ROM/CK and inflammatory-marker definitions, prospective hierarchy, denominators, analysis and CI." } ], "reports": [ { "report_id": "S01", "title": "Ginger (Zingiber officinale) reduces muscle pain caused by eccentric exercise", "url": "https://pubmed.ncbi.nlm.nih.gov/20418184/", "report_type": "Retained summary of 2 randomized, double-blind, placebo-controlled experiments by the same team", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "study_family": "Formulation experiments in the same paper and team; direct between-formulation effects and independent replication remain unverified", "independent_replication": "S01 contains two formulation experiments in the same paper, team and protocol. This sheet selects raw powder versus placebo; the heat-treated result is not added as independent-team replication or a direct between-formulation effect. S02 is a separate single-dose crossover report with a negative observation, using a different regimen. The formulation mapping of 34 and 40, total unique participants and participant overlap between reports remain unverified.", "observed_result": "Raw powder 25%, −0.78 SD, P=.041; heat-treated powder 23%, −0.57 SD, P=.049", "source_evidence_date": "2026-09-08", "materials": [ { "material_type": "External PubMed bibliography/abstract index", "acquired": false, "actually_read": "Not read", "qualification": "This is a retained PubMed link. Its current response, bibliographic identity and the public availability, acquisition or reading of the abstract and full text have not been verified. The selected raw-powder report is distinguished from the heat-treated result. The samples of 34 and 40 are not assigned, summed or halved into formulation-specific or per-arm analysis counts. Denominators, the SD definition, CI, ITT/SAP and actual harm material remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "DOI identifier entry point", "acquired": false, "actually_read": "Not read", "qualification": "This entry point is constructed from the retained DOI and distinguished from the original URL field. Current version, response, physical document form, acquisition and reading remain unverified. The selected raw-powder report is distinguished from the heat-treated result. The samples of 34 and 40 are not assigned, summed or halved into formulation-specific or per-arm analysis counts. Denominators, the SD definition, CI, ITT/SAP and actual harm material remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "Original full text", "acquired": false, "actually_read": "Not read", "qualification": "No exact full-text file, download URL or document form has been acquired. Existence, public availability, acquisition and reading remain unverified. The selected raw-powder report is distinguished from the heat-treated result. The samples of 34 and 40 are not assigned, summed or halved into formulation-specific or per-arm analysis counts. Denominators, the SD definition, CI, ITT/SAP and actual harm material remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "Registration material needed", "acquired": false, "actually_read": "Not read", "qualification": "This is an item of material needed for later verification. Registration identity, URL and existence remain unverified; the original inability to identify registration does not establish that the trial was unregistered. The selected raw-powder report is distinguished from the heat-treated result. The samples of 34 and 40 are not assigned, summed or halved into formulation-specific or per-arm analysis counts. Denominators, the SD definition, CI, ITT/SAP and actual harm material remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "Protocol/statistical-analysis-plan material needed", "acquired": false, "actually_read": "Not read", "qualification": "This is an item of material needed for later verification. Existence, URL and prospective version of planning documents remain unverified. It is not counted as an identified external document. The selected raw-powder report is distinguished from the heat-treated result. The samples of 34 and 40 are not assigned, summed or halved into formulation-specific or per-arm analysis counts. Denominators, the SD definition, CI, ITT/SAP and actual harm material remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "Stored existing review summary", "acquired": true, "actually_read": "Stored existing review summary read", "public_status": "Locally acquired; summary read", "as_of": null, "access_status": "Acquired", "qualification": "The retained Korean/English research/bibliographic summaries and case-specific conditions/application records were read. This is not a new reading of the original abstract, full text or registration. The selected raw-powder report is distinguished from the heat-treated result. The samples of 34 and 40 are not assigned, summed or halved into formulation-specific or per-arm analysis counts. Denominators, the SD definition, CI, ITT/SAP and actual harm material remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time." } ], "links": [ { "label": "PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/20418184/" } ], "result_level": "These are retained reports for each formulation versus placebo. This sheet selects raw powder. The original SD label is retained; its formal measure, calculation, denominator, exact effect/CI and analysis population remain unverified. This is not a new full-text verification, recalculation or formulation-specific verdict.", "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified." }, { "report_id": "S02", "title": "Acute effects of dietary ginger on muscle pain induced by eccentric exercise", "url": "https://pubmed.ncbi.nlm.nih.gov/19164834/", "report_type": "Retained summary of a separate single-dose randomized, placebo-controlled crossover trial", "acquired_read": "The retained Korean/English summaries and case-specific conditions/application records were read. Linked external abstracts, full texts, registration and planning material remain unread, with no access attempt.", "study_family": "Separate single-dose crossover trial; formulation matching and participant overlap with the selected comparison remain unverified", "independent_replication": "S01 contains two formulation experiments in the same paper, team and protocol. This sheet selects raw powder versus placebo; the heat-treated result is not added as independent-team replication or a direct between-formulation effect. S02 is a separate single-dose crossover report with a negative observation, using a different regimen. The formulation mapping of 34 and 40, total unique participants and participant overlap between reports remain unverified.", "observed_result": "Retained report of no clinically or statistically meaningful effect with a single 2 g dose", "source_evidence_date": "2026-09-08", "materials": [ { "material_type": "External PubMed bibliography/abstract index", "acquired": false, "actually_read": "Not read", "qualification": "This is a retained PubMed link. Its current response, bibliographic identity and the public availability, acquisition or reading of the abstract and full text have not been verified. The single 2 g dose in a crossover trial reporting 25 people is not direct replication of the selected 11-day repeated regimen. Formulation, exact dosing time, period-specific denominators and participant overlap remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "DOI identifier entry point", "acquired": false, "actually_read": "Not read", "qualification": "This entry point is constructed from the retained DOI and distinguished from the original URL field. Current version, response, physical document form, acquisition and reading remain unverified. The single 2 g dose in a crossover trial reporting 25 people is not direct replication of the selected 11-day repeated regimen. Formulation, exact dosing time, period-specific denominators and participant overlap remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "Original full text", "acquired": false, "actually_read": "Not read", "qualification": "No exact full-text file, download URL or document form has been acquired. Existence, public availability, acquisition and reading remain unverified. The single 2 g dose in a crossover trial reporting 25 people is not direct replication of the selected 11-day repeated regimen. Formulation, exact dosing time, period-specific denominators and participant overlap remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "Registration material needed", "acquired": false, "actually_read": "Not read", "qualification": "This is an item of material needed for later verification. Registration identity, URL and existence remain unverified; the original inability to identify registration does not establish that the trial was unregistered. The single 2 g dose in a crossover trial reporting 25 people is not direct replication of the selected 11-day repeated regimen. Formulation, exact dosing time, period-specific denominators and participant overlap remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "Protocol/statistical-analysis-plan material needed", "acquired": false, "actually_read": "Not read", "qualification": "This is an item of material needed for later verification. Existence, URL and prospective version of planning documents remain unverified. It is not counted as an identified external document. The single 2 g dose in a crossover trial reporting 25 people is not direct replication of the selected 11-day repeated regimen. Formulation, exact dosing time, period-specific denominators and participant overlap remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time.", "public_status": "Existence/public availability/acquisition unverified; unread", "as_of": null, "access_status": "Not attempted" }, { "material_type": "Stored existing review summary", "acquired": true, "actually_read": "Stored existing review summary read", "public_status": "Locally acquired; summary read", "as_of": null, "access_status": "Acquired", "qualification": "The retained Korean/English research/bibliographic summaries and case-specific conditions/application records were read. This is not a new reading of the original abstract, full text or registration. The single 2 g dose in a crossover trial reporting 25 people is not direct replication of the selected 11-day repeated regimen. Formulation, exact dosing time, period-specific denominators and participant overlap remain unverified. 2026-10-06 is the retained-summary review date. No per-material reading date is recorded, and external material was neither accessed nor read in this work. The original verdict date 2026-09-08 and English-wording correction date 2026-09-14 are not changed into new-search or external-full-text-reading dates. Historical self-review, pending flags and display-change records are preserved as records of their time." } ], "links": [ { "label": "PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/19164834/" } ], "result_level": "The negative observation under a different regimen is retained. The Korean wording immediately before exercise and the English immediately around exercise remain distinct; exact timing, formulation, crossover periods, analysis denominators and CI remain unverified. This is not new proof of no effect or equivalence.", "existence": "Stored research/bibliographic summaries exist. Existence, public availability, acquisition and reading of external abstracts, full texts, registration, protocols, analysis plans and original product/support/harm material remain separately unverified." } ], "method_sources": [ { "id": "M03", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03", "section": "§3.1, §3.2.1–3.2.3, MECIR C5/C7/C13", "official_principle": "Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M04", "version": "Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04", "section": "§4.5, §4.6.1–4.6.3, MECIR C42", "official_principle": "Distinguish studies from reports and link them; do not omit a study solely because results are unreported.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M08", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08", "section": "§8.1–8.2.3, Table 8.2.a", "official_principle": "Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M15", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2023-08", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15", "section": "§15.2.4, §15.3.1–15.3.3", "official_principle": "Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." }, { "id": "M19", "version": "Cochrane Handbook 6.5 (2024), chapter updated 2019-10", "url": "https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19", "section": "§19.1.2, §19.2.1–19.2.4", "official_principle": "Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates.", "review_level": "Retained method-application records were reused. External originals were not reread and method content was not reassessed." } ], "status_dictionary": { "Met": "Limited verification of the retained identity, observation or scope required by this item. This is separate from clinical sufficiency or full-text certification.", "Partly verified": "Some facts needed for the question are known, while the stated analysis, population, formulation, denominator or other details remain unverified.", "Unverified": "Direct information for this question has not been verified within the retained scope. This does not mean effect 0, no research, no harm or an unreviewed sheet.", "Not applicable": "An extension obligation outside the narrow question does not apply. This is not a replacement state for unread or unverified material.", "Not applicable (display alias)": "An alternate grey display label for Not applicable.", "Not read": "No current direct reading of external material. This is separate from reading the retained local summary.", "Conflicting data": "An actual inconsistency between reports under the same regimen; differences between questions alone do not establish a conflict." }, "study_overlap": { "state": "Unverified", "unique_trial_count": null, "unique_participant_count": null, "reason": "S01 contains two formulation experiments in the same paper, team and protocol. This sheet selects raw powder versus placebo; the heat-treated result is not added as independent-team replication or a direct between-formulation effect. S02 is a separate single-dose crossover report with a negative observation, using a different regimen. The formulation mapping of 34 and 40, total unique participants and participant overlap between reports remain unverified." }, "history": [ { "date": "2026-10-25", "kind": "Separation of public-facing pages and materials", "view_version": "1.0", "change": "The public view and materials were prepared from the existing 36 items. No new clinical search, verification-state change or scoring was performed." } ], "language": "en", "translation_date": "2026-10-25" }